Guanfacine Dosing and Management
For ADHD treatment with extended-release guanfacine (Intuniv), start at 1 mg once daily and titrate by 1 mg weekly to a target range of 1-4 mg/day, with optimal dosing at 0.05-0.12 mg/kg once daily based on clinical response and tolerability. 1
Dosing Regimens
Extended-Release Guanfacine (Intuniv) for ADHD
Starting dose: 1 mg once daily, taken either morning or evening at the same time each day 2, 1
Titration schedule:
- Increase by no more than 1 mg per week 1
- Target dose range: 1-4 mg once daily for both monotherapy and adjunctive therapy with stimulants 2, 1
- Weight-based dosing is preferred: Start at 0.05-0.08 mg/kg once daily, with doses up to 0.12 mg/kg once daily providing additional benefit if tolerated 3, 1
- Maximum studied dose: 4 mg/day in standard practice, though doses up to 8 mg/day may be considered with CYP3A4 inducers 1
Important administration details:
- Do NOT administer with high-fat meals (increases drug exposure) 1
- Swallow tablets whole - do not crush, chew, or break (increases release rate) 1
- Available tablet strengths: 1,2,3, and 4 mg 2, 1
Immediate-Release Guanfacine for Hypertension
While the evidence focuses primarily on extended-release formulations for ADHD, immediate-release guanfacine for hypertension typically starts at lower doses. Do NOT substitute immediate-release for extended-release on a mg-per-mg basis due to different pharmacokinetic profiles (extended-release has delayed Tmax, reduced Cmax, and lower bioavailability) 1.
Drug Interactions Requiring Dose Adjustment
Strong CYP3A4 Inhibitors 1, 4
Examples: ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice
Dosing adjustments:
- Initiating guanfacine while on inhibitor: Limit dose to 2 mg/day maximum
- Adding inhibitor to existing guanfacine: Decrease guanfacine dose by half
- Stopping inhibitor: Double guanfacine dose based on tolerability (max 4 mg/day)
Strong CYP3A4 Inducers 1, 4
Examples: rifampin, carbamazepine, phenytoin, St. John's wort
Dosing adjustments:
- Initiating guanfacine while on inducer: May titrate up to 8 mg/day; consider faster titration (2 mg/week increments)
- Adding inducer to existing guanfacine: Increase dose gradually over 1-2 weeks to 2-fold the original dose based on tolerability
- Stopping inducer: Decrease dose by half over 1-2 weeks (max 4 mg/day)
Moderate CYP3A4 Inhibitors/Inducers 4
Model predictions suggest moderate inhibitors (erythromycin, fluconazole) increase guanfacine exposure 2-2.3-fold, while moderate inducers (efavirenz) reduce exposure to 33-58% of baseline. Apply similar dose adjustment principles as for strong inhibitors/inducers, with 50% dose reduction for moderate inhibitors and consideration for dose increases with moderate inducers.
Monitoring Parameters
Cardiovascular Monitoring 2, 5
Before initiation:
- Blood pressure (BP) and heart rate (HR)
- Personal and family cardiac history (sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome)
- Consider ECG if risk factors present
During treatment:
- Monitor pulse and blood pressure prior to initiation, after each dose increase, and periodically during maintenance 2, 5
- Expected changes: Small decreases in HR (average 1-2 bpm) and BP (1-4 mmHg) 5, 6
- Dose-related risks for hypotension, bradycardia, and sedation 2, 1
Recent research shows guanfacine causes significant HR reduction (-12.3 bpm) and QT interval prolongation (+16.8 ms), though without clinically meaningful changes in advanced ECG markers 6. Serial vital sign monitoring was completed in only 54% of cases in one audit, highlighting a common pitfall 7.
Clinical Response Monitoring 8, 5
- ADHD symptom scales (ADHD Rating Scale-IV)
- Clinical Global Impression of Improvement
- Functional impairment and quality of life measures
- Treatment effects typically observed within 2-4 weeks (slower onset than stimulants) 2
Common Adverse Effects to Monitor 2, 5
Most frequent (≥5%): somnolence, fatigue, sedation, headache, irritability, insomnia, nightmares, abdominal pain, nausea, dizziness, dry mouth 2
Critical safety considerations:
- Somnolence/sedation emerge within first 2 weeks and generally resolve by study end 9
- Adjunctive therapy with stimulants associated with fewer side effects than monotherapy (26.7% vs 50.0%), particularly in autism (20.0% vs 51.6%) 7
- Rare but serious: bradycardia, syncope, hypotension requiring discontinuation 2
Discontinuation Guidelines
Taper gradually to minimize rebound hypertension: Decrease by no more than 1 mg every 3-7 days 1, 10
Abrupt discontinuation can cause transient BP elevations above baseline, though one study in healthy young adults found no clinically significant rebound with abrupt cessation 10. However, tapering remains the recommended approach in clinical practice to minimize risk 1.
Missed Doses
After two or more consecutive missed doses, consider re-titration based on patient tolerability rather than resuming the previous maintenance dose 1.
Special Populations
Hepatic or Renal Impairment 1
Dose reduction may be required in patients with clinically significant hepatic or renal impairment, as guanfacine is primarily metabolized via CYP3A4 and excreted renally 2.
Pregnancy and Breastfeeding 3
- Overall recommendation: Caution advised
- Limited data: One study of 30 patients with preeclampsia (all beyond first trimester) showed no congenital malformations but 20% low birth weight 3
- No published breastfeeding studies; guanfacine found in human milk with M:P ratio of 2 for clonidine (similar agent) 3
- Alternative agents preferred when possible 3
Clinical Efficacy Context
Guanfacine is a second-line treatment for ADHD with effect size ~0.7 compared to stimulants' effect size of ~1.0 2, 8. It provides "around-the-clock" effects and is uncontrolled, making it useful for:
- Stimulant non-responders or intolerance
- Comorbid sleep disorders, tic/Tourette's disorder, or substance use disorders 2
- Adjunctive therapy with stimulants (FDA-approved) 8, 5, 1
In Europe, guanfacine is approved only when stimulants are unsuitable, not tolerated, or ineffective 2. The 2022 Japanese guidelines recommend it as first-line pharmacological treatment alongside OROS-MPH and atomoxetine 11.
Periodic re-evaluation of long-term treatment (>9 weeks) is recommended, as systematic controlled trials beyond this duration are limited 1.